<DOC>
	<DOCNO>NCT00675649</DOCNO>
	<brief_summary>The purpose study assess safety effect ( good bad ) golimumab therapy patient severe , persistent asthma .</brief_summary>
	<brief_title>A Clinical Trial Evaluating Safety Effectiveness Golimumab Patients With Severe , Persistent Asthma</brief_title>
	<detailed_description>Golimumab type tumor necrosis factor ( TNF ) inhibitor . TNF naturally occur substance body substance may cause long-term inflammation . Golimumab may help treat disease block activity TNF body reduce symptom severe , persistent asthma.This study assess safety effectiveness subcutaneously ( skin ) administer golimumab determine reduction sign symptoms patient active severe , persistent asthma . The effect subcutaneously ( SC ) administer golimumab quality life patient severe , persistent asthma also assess . About 200 patient take part study approximately 60 center worldwide . Participation study last 42 week . The study consist 3 phase : screening phase ( last 1 4 week ) , treatment phase ( 20 week ) , follow-up phase ( 20 week ) . Visits schedule occur every 4 week treatment follow-up phase study . Patients eligible take part study randomly place one follow study group : Group 1 : Placebo ( inactive dummy treatment look study drug , golimumab , contain active medication ) Week 0 Week 20 . Group 2 : Golimumab 100 mg Week 0 Week 20 . This study `` blind . '' This mean neither patient study doctor know group patient place . However , need safety health reason , study doctor find patient 's study group time . Patients receive injection ( skin ) placebo ( Group 1 ) golimumab 100 mg ( Group 2 ) every 4 week Week 0 Week 20 .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Physician diagnosis asthma &gt; = 3 year diagnosis severe , persistent asthma &gt; = 1 year prior screen Reversible airway obstruction Continuous treatment high dose inhale corticosteroid longacting Beta2agonist least 3 month prior screen At least 1 occasion previous 6 month worsen asthma require treatment additional steroid ( intravenous oral ) Score &gt; = 2 point Asthma Control Questionnaire ( ACQ ) screen Diagnosis chronic obstructive pulmonary disease ( COPD ) , cystic fibrosis , significant respiratory disorder Lifethreatening asthma attack require intubation 6month period prior screen Steroid use dose &gt; 20 mg prednisone screen visit Known malignancy history malignancy Previous exposure antiTNF therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Injections</keyword>
	<keyword>Severe , persistent asthma</keyword>
</DOC>